Sphera Funds Management’s Melinta Therapeutics, Inc. Common Stock MLNT Stock Holding History

Sphera Funds Management’s Portfolio MLNT Stock Details MLNT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-323,373	Closed	-$1.28M	–	134
2018 Q4	$1.28M	Hold	323,373	–	–	0.14%	85
2018 Q3	$6.39M	Buy	323,373 +126,475	+64%	+$3.2M	0.73%	33
2018 Q2	$6.25M	Buy	196,898 +148,119	+304%	+$5.33M	0.86%	30
2018 Q1	$1.8M	Buy	48,779 +8,779	+22%	+$577K	0.27%	78
2017 Q4	$3.16M	Buy	+40,000	New	+$2.96M	0.37%	66

Other funds holding MLNT

Isthmus Partners Madison, Wisconsin $953M AUM 18.74% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

ZIM

Zacks Investment Management Chicago, Illinois $12.5B AUM 29.36% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Sphera Funds Management's MLNT Position: Q1 2019 in Review

Sphera Funds Management sold out of Melinta Therapeutics, Inc. Common Stock (MLNT) in Q1 2019, closing a stake of 323,373 shares — an estimated $1.28M sold.

Sphera Funds Management first reported a position in MLNT in Q4 2017 and held it in 5 quarters. The position peaked at $6.39M in Q3 2018. 52 funds tracked by Wall St. Rank hold MLNT as of Q1 2019.

Sphera Funds Management reported no remaining Melinta Therapeutics, Inc. Common Stock position as of Q1 2019 after selling out during the quarter.
Sphera Funds Management sold 323,373 Melinta Therapeutics, Inc. Common Stock shares in Q1 2019, an estimated $1.28M.
Sphera Funds Management first reported a position in Melinta Therapeutics, Inc. Common Stock in Q4 2017 and held it in 5 quarters.
Sphera Funds Management's Melinta Therapeutics, Inc. Common Stock position peaked at $6.39M in Q3 2018.
52 funds tracked by Wall St. Rank held Melinta Therapeutics, Inc. Common Stock as of Q1 2019.

Based on Sphera Funds Management's 13F filing for Q1 2019, filed 15 May 2019.